Achieve Life Sciences' Participation in the BTIG Conference
SEATTLE and VANCOUVER, British Columbia – Achieve Life Sciences, Inc. (NASDAQ: ACHV) is a notable player in the realm of specialty pharmaceuticals, focusing on the innovative development and marketing of cytisinicline as a remedy for nicotine dependence, particularly pivotal for smoking cessation. The company recently announced its involvement in the BTIG Virtual Biotechnology Conference scheduled to take place in the near future.
Key Insights From the Conference Event
During this important virtual gathering, Rick Stewart, the Chief Executive Officer of Achieve Life Sciences, will engage in a fireside chat alongside Julian Harrison, a recognized analyst in biotechnology at BTIG. This dialogue is set for a later part of the day, offering a unique perspective on the strategic directions and advancements in Achieve’s clinical development.
Understanding Cytisinicline's Role
Cytisinicline has emerged as a promising solution for those attempting to quit smoking. The FDA recently granted Breakthrough Therapy designation to cytisinicline, reflecting its potential in addressing a significant public health challenge – nicotine addiction, particularly among adults. Achieve Life Sciences is actively pursuing regulatory approval for this treatment based on compelling data from comprehensive Phase 3 clinical studies.
Nicotine Dependence Statistics
The statistics surrounding smoking and nicotine dependence are staggering. Currently, approximately 29 million adults in the United States smoke combustible cigarettes. In fact, tobacco use remains the primary cause of preventable deaths globally, with over eight million fatalities each year. Furthermore, a significant number of deaths related to lung cancer, pulmonary diseases, and coronary heart diseases are closely linked to smoking and secondhand smoke exposure. The rising usage of e-cigarettes has also drawn attention, as about 17 million adults in the U.S. now use vaping devices, often perceived as safer alternatives.
Future of Smoking Cessation Treatments
In response to the growing prevalence of nicotine use, Achieve Life Sciences has made remarkable progress in its clinical trials to bring effective treatment options to those striving to overcome their dependency. The company's recent submission of a New Drug Application to the FDA underscores its commitment to this mission. The clinical data collected from the completed Phase 3 trials demonstrated positive outcomes, indicating that cytisinicline can significantly help adults in quitting smoking.
The Mechanism Behind Cytisinicline
Cytisinicline's unique action as a plant-based alkaloid sets it apart from other treatments. By binding effectively to nicotinic acetylcholine receptors in the brain, it helps mitigate cravings and diminishes the enjoyable feelings linked to nicotine consumption. This dual action not only aids in reducing symptoms of cravings but also lowers the satisfaction derived from tobacco products, making it a vital option for cessation.
Looking Towards The Future
With ongoing research and commitment to tackling nicotine dependence, Achieve Life Sciences is on a promising path facilitated by its recent developments and data-driven approach. The leadership of the company, embodied by executives like Rick Stewart, reflects a proactive stance towards innovation in the public health sector. Their participation in key conferences like BTIG allows them to share insights and garner support from investors while paving the way for future collaborations.
Frequently Asked Questions
What is Achieve Life Sciences?
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline to treat nicotine dependence and smoking cessation.
What is cytisinicline?
Cytisinicline is a plant-based alkaloid that has shown promise in treating nicotine addiction by reducing cravings and the satisfaction associated with nicotine use.
Why is the BTIG conference significant for Achieve?
The BTIG conference provides Achieve with a platform to share developments about cytisinicline and connect with potential investors and stakeholders in the biotechnology sector.
How is cytisinicline administered?
Cytisinicline is administered as a prescription treatment, specifically tailored for adults seeking to quit smoking or using e-cigarettes.
What is the future outlook for cytisinicline?
The outlook appears positive as Achieve Life Sciences progresses with clinical trials and aims for FDA approval, positioning cytisinicline as a vital option in nicotine cessation therapies.
